Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib for elderly atopic dermatitis (real-world observational study)
ChiCTR2500112704Phase 4Recruiting
- Sponsor
- Puren Hospital Affiliated to Wuhan University of Science and Technology
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of abrocitinib in atopic dermatitis (AD), sponsored by Puren Hospital Affiliated to Wuhan University of Science and Technology. Primary endpoints: Eczema Area and Severity Index (EASI) score, Atopic dermatitis score index and 2 more. Started Nov 2025; status: recruiting.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2500112704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112704.